share_log

サンバイオ---ストップ高買い気配、主要開発品「SB623」の米新規特許が成立

SanBio - With a purchasing atmosphere of limit up, new US patents for their major development product "SB623" have been approved.

Fisco Japan ·  Jul 25 21:47


There is a buying atmosphere of limit-up. After the close of trading on the 25th, it was announced that a new patent related to the cell therapy of chronic cerebral infarction using the main development product "SB623" has been granted in the United States, which is considered to be good news. As part of maximizing corporate value, the company is striving to build and maintain a patent portfolio, but with this patent acquisition, the period of application patent for the treatment of chronic cerebral infarction with"SB623" in the largest market, the United States, has been significantly extended.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment